EP2756061A1 - Compositions pour solubiliser des cellules et/ou un tissu - Google Patents

Compositions pour solubiliser des cellules et/ou un tissu

Info

Publication number
EP2756061A1
EP2756061A1 EP12876815.7A EP12876815A EP2756061A1 EP 2756061 A1 EP2756061 A1 EP 2756061A1 EP 12876815 A EP12876815 A EP 12876815A EP 2756061 A1 EP2756061 A1 EP 2756061A1
Authority
EP
European Patent Office
Prior art keywords
brij
composition
skin
tissue
analyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12876815.7A
Other languages
German (de)
English (en)
Other versions
EP2756061A4 (fr
Inventor
Byeong Hee HWANG
Samir Mitragotri
Russell M. Lebovitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DX Biosciences Inc
University of California
Original Assignee
DX Biosciences Inc
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DX Biosciences Inc, University of California filed Critical DX Biosciences Inc
Priority to EP16161790.7A priority Critical patent/EP3056559B1/fr
Publication of EP2756061A1 publication Critical patent/EP2756061A1/fr
Publication of EP2756061A4 publication Critical patent/EP2756061A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/54—Polymers characterized by specific structures/properties
    • A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
    • A61K2800/5422—Polymers characterized by specific structures/properties characterized by the charge nonionic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/54—Polymers characterized by specific structures/properties
    • A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
    • A61K2800/5428—Polymers characterized by specific structures/properties characterized by the charge amphoteric or zwitterionic

Definitions

  • Skin is the "window" to the body. Skin is unique among the body's organs for several reasons: (1) skin is the largest organ of the human body; (2) skin is directly exposed to the environment; (3) skin is an excellent excretory organ; (4) skin is the most visible and accessible organ of the body; and (5) skin is a highly active immune organ of the body.
  • Skin has another important quality: The molecular profile of skin has information that is valuable for physiological monitoring of, among other things, small organic molecules, proteins, DNA, RNA, and lipids. Much can be learned from skin's molecular profiling. For example, pathogens (e.g., bacteria) that grow on skin may allow for forensic identification. Skin's molecular profile may reveal environmental factors to which the body has been passively exposed. These environmental factors may range from the mundane, e.g., allergens, toxins, and cosmetic products, to the industrial and/or agricultural, e.g., industrial solvents, fertilizers, and pesticides, to the dangerous, e.g., explosives and other warfare agents.
  • pathogens e.g., bacteria
  • Skin's molecular profile may also reveal factors to which the body has been actively exposed. More particularly, skin's molecular profile may reveal what the body has consumed. For example, abused substances (e.g., illegal drugs or narcotics) and therapeutic drugs (e.g., tramadol, fluconazole, barbitals, and anabolic steroids) may be found in skin weeks after consumption.
  • abused substances e.g., illegal drugs or narcotics
  • therapeutic drugs e.g., tramadol, fluconazole, barbitals, and anabolic steroids
  • Skin's molecular profile may also aid diagnosis of conditions and diseases. For example, skin cholesterol is a proxy of the extent of arterial blocks. Glycation of skin collagen is an indicator of a history of diabetes. Skin deposition of ⁇ -amyloids may indicate the existence and extent of Alzheimer's disease. And skin globular proteins (e.g., IgE) may indicate allergies to specific allergens.
  • skin globular proteins e.g., IgE
  • CTAB a cationic surfactant
  • CTAB a cationic surfactant
  • skin can also be a host to myriad undesirable cosmetic conditions, such as age spots, skin tags, seborrheic keratosis, scar tissues, xanthomas, non-cancerous hyperproliferative conditions, surface bumps, and scaly patches; and therapeutic conditions such as skin tumors, actinic keratosis, leukoplakia, and surface cancers relating to Barrett's esophagus and right-colon pre-cancer plaque. For these conditions, solubilization and remodeling or removal may be the primary concern, with or without subsequent diagnostic processing.
  • compositions for skin sampling as well as for mucosal membrane and other tissue sampling, which, when used in conjunction with applied energy, at least partially solubilize such skin, mucosal membrane, and other tissue.
  • composition comprising:
  • a zwitterionic surfactant comprising:
  • a non-ionic surfactant comprising:
  • a method for solubilizing and remodeling and/or removing tissue on or beneath a patient's skin comprising optionally applying energy to a region of interest on the skin; and contacting the region with a tissue solubilizing composition.
  • a method for recovering analytes from mucosal membrane, skin, or other tissue comprising: optionally applying energy to a region of interest on the mucosal membrane, skin, or other tissue containing at least one analyte; contacting the region with a tissue solubilizing composition, thereby solubilizing at least some of the mucosal membrane, skin, or other tissue containing at least one analyte; and collecting the at least one analyte from the solubilized mucosal membrane, skin, and other tissue.
  • Figure 1 illustrates in graphical form the total protein (mg/ml) recovered from porcine skin when the porcine skin is contacted with various combinations of zwitterionic and nonionic surfactants in the presence of ultrasound.
  • Figure 2 illustrates in graphical form the soluble protein (mg/ml) recovered from porcine skin when the porcine skin is contacted with various combinations of zwitterionic and nonionic surfactants in the presence of ultrasound.
  • Figure 3 illustrates the dependence on concentration of the protein extraction efficacy from porcine skin of TPS:Brij CIO.
  • Figure 4 illustrates in graphical form the preserved activity of the intracellular enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in various combinations of zwitterionic and nonionic surfactants.
  • GPDH glyceraldehyde 3-phosphate dehydrogenase
  • Figure 5 illustrates in graphical form the combined dependence of soluble protein extraction efficacy and GAPDH stability in various combinations of zwitterionic and nonionic surfactants.
  • Figure 6 illustrates the total protein recovery from Human Epidermal
  • Figure 9 illustrates the total protein recovered from homogenized mouse skin using various reagents.
  • Figure 10 illustrates the specific GAPDH activity measured in homogenized mouse skin using various reagents.
  • composition comprising:
  • a zwitterionic surfactant comprising:
  • n 10, 12, 14, 16, or 18;
  • a non-ionic surfactant comprising:
  • the zwitterionic surfactant comprises DPS and the nonionic surfactant comprises at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58. In one embodiment, the combination of DPS:Brij 30 is excluded. [0029] In another embodiment, the zwitterionic surfactant comprises DDPS and the nonionic surfactant comprises at least one of Brij 30, Brij 35, Brij 52, Brij CI O, and Brij 58.
  • the zwitterionic surfactant comprises TPS and the nonionic surfactant comprises at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58.
  • the zwitterionic surfactant comprises HPS and the nonionic surfactant comprises at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58. In one embodiment, the combination of HPS:Brij 35 is excluded.
  • the zwitterionic surfactant comprises OPS and the nonionic surfactant comprises at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58.
  • the zwitterionic surfactant and the nonionic surfactant may be dissolved in a buffer solution.
  • PBS phosphate-buffered saline
  • EDTA ethylenediaminetetraacetic acid
  • the surfactant combination may have a pH of greater than about 7.0 in buffer solution, between about 7.0 and 9.0 in buffer solution, between about 7.4 and 9.0 in buffer solution, between about 7.4 and 8.0 in buffer solution, and between about 7.2 and 7.6 in buffer solution.
  • the zwitterionic surfactant and the nonionic surfactant may be present in a total concentration of between about 0.01% and about 10% (w/v) in the buffer solution.
  • the zwitterionic surfactant and the nonionic surfactant may be present in a total concentration of about 0.01% to about 5% (w/v) in the buffer solution, including total concentrations of about 0.1% (w/v) to about 2% (w/v) in the buffer solution, about 1% (w/v) in the buffer solution, and about 0.1 % (w/v) to about 0.5% (w/v) in the buffer solution.
  • the zwitterionic surfactant and the nonionic surfactant are present in a total concentration of about 0.5% (w/v) in the buffer solution. In another embodiment, the zwitterionic surfactant and the nonionic surfactant may be present in a ratio of about 3: 1 to about 1 :3 or about 3:2 to about 2:3. In one embodiment, the zwitterionic surfactant and the nonionic surfactant may be present in a ratio of about 1 : 1.
  • the zwitterionic surfactan nonionic surfactant composition may have several applications.
  • a method for solubilizing and remodeling and/or removing tissue on or beneath a patient's skin comprising applying energy to a region of interest on the skin; and contacting the region with a tissue solubilizing composition comprising at least one of: ( 1 ) DPS and at least one of Brij 30, Brij 35, Brij 52, Brij CI O, and Brij 58; (2) DDPS and at least one of Brij 30, Brij 35, Brij 52, Brij C IO, and Brij 58; (3) TPS and at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58; (4) HPS and at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58; and (5) OPS and at least one of Brij 30, Brij 35, Brij 52, Brij C I O, and Brij 58.
  • a method for recovering analytes from mucosal membrane, skin, or other tissue comprising: applying energy to a region of interest on the mucosal membrane, skin, or other tissue containing at least one analyte; contacting the region with a tissue solubilizing composition, the tissue solubilizing composition comprising at least one of: (1 ) DPS and at least one of Brij 30, Brij 35, Brij 52, Brij C I O, and Brij 58; (2) DDPS and at least one of Brij 30, Brij 35, Brij 52, Brij C I O, and Brij 58; (3) TPS and at least one of Brij 30, Brij 35, Brij 52, Brij C I O, and Brij 58; (4) HPS and at least one of Brij 30, Brij 35, Brij 52, Brij CI O, and Brij 58; and (5) OPS and at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58; and (5) OPS and at least one of
  • tissue may include breast, prostate, eye, vagina, bladder, nail, hair, colon, testicles, intestine, lung, brain, pancreas, liver, heart, bone, or aorta wall.
  • an "analyte” may include any biomolecule, drug, small molecule, warfare agent, environmental contaminant, microbe, and the like that is present in or on the tissue and can be extracted from the tissue of interest.
  • biomolecules may include proteins (e.g., disease biomarkers such as cancer biomarkers, antibodies: IgE, IgG, IgA, IgD, or IgM, and the like), peptides, lipids (e.g., cholesterol, ceramides, and fatty acids), nucleic acids (e.g., RNA and DNA), small molecules (e.g., glucose, urea, and creatine), small molecule drugs or metabolites of small molecule drugs, microbes, inorganic molecules, elements, and ions (e.g., iron, Ca 2+ , K + , Na + , and the like).
  • the biomolecule is exclusive of glucose and cancer markers.
  • drugs may include abused drugs, such as, for example, cocaine, heroin, methyl amphetamine, and prescription drugs taken in excess of dosage, or taken without a prescription (e.g., painkillers such as opioids); and therapeutic drugs, such as, for example, tramadol, fluconazole, barbitals, and anabolic steroids.
  • warfare agents may include any molecule, compound, or composition of either biological or chemical origin that may be used as a weapon.
  • warfare agents include explosives, nerve gases (e.g., VX and Sarin), phosgene, toxins, spores (e.g., anthrax), and the like.
  • "environmental contaminants” may include any molecule, compound, or composition that can be detrimental to an individual, e.g., when at concentrations elevated above a risk threshold.
  • Examples include water pollutants (e.g., fertilizers, pesticides, fungicides, insecticides, herbicides, heavy metals, and halides), soil pollutants (e.g., fertilizers, pesticides, fungicides, insecticides, herbicides, heavy metals, and halides), and air pollutants (e.g., NO x , SO x , greenhouse gases, persistent organic pollutants, particulate matter, and smog).
  • water pollutants e.g., fertilizers, pesticides, fungicides, insecticides, herbicides, heavy metals, and halides
  • soil pollutants e.g., fertilizers, pesticides, fungicides, insecticides, herbicides, heavy metals, and halides
  • air pollutants e.g., NO x , SO x , greenhouse gases, persistent
  • solubilizing the target cells and tissue includes the application of energy.
  • the energy may be applied by any number of suitable methods, including mechanical (e.g., abrasion, shear, vacuum, pressure, suction, ultrasound), optical (e.g., laser), thermal, and electrical energy.
  • mechanical e.g., abrasion, shear, vacuum, pressure, suction, ultrasound
  • optical e.g., laser
  • thermal e.g., heat
  • Suitable energy applicators are disclosed in U.S. Patent Application Serial Nos. 12/664,994, 13/126, 105, and 13/095,771, each of which is incorporated by reference herein in its entirety.
  • the compositions may be used for solubilizing cells for in vitro protein recovery.
  • the compositions may provide a benefit of preservation of bioactivity.
  • the compositions may also possess the ability to quickly ⁇ solubilize various tissues, including those with durable mechanical properties, such as skin.
  • a protease inhibitor may be included in the compositions.
  • the compositions may be able to preserve the biological activity of proteins.
  • the compositions are also applicable in vivo. In particular, the compositions may be able to recover labile phosphoproteins with RPPA, thus opening the possibility of quickly and non-invasively probing multiple signaling pathways.
  • the compositions may be useful as antibacterial compositions.
  • a method for inhibiting the growth and reproduction of bacteria and/or treating a bacterial infection comprising applying an antibacterial composition to an area that is subject to attack by the bacteria, the antibacterial composition comprising at least one of: (1) DPS and at least one of Brij 30, Brij 35, Brij 52, Brij C I O, and Brij 58; (2) DDPS and at least one of Brij 30, Brij 35, Brij 52, Brij C I O, and Brij 58; (3) TPS and at least one of Brij 30, Brij 35, Brij 52, Brij CI O, and Brij 58; (4) HPS and at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58; and (5) OPS and at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58.
  • the method may further include the application of energy.
  • a method for solubilizing cells and/or tissues comprising contacting the cells and/or tissues with a composition, the composition comprising at least one of: (1) DPS and at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58; (2) DDPS and at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58; (3) TPS and at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58; (4) HPS and at least one of Brij 30, Brij 35, Brij 52, Brij C IO, and Brij 58; and (5) OPS and at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58.
  • proteins including cytosolic proteins, nuclear proteins, and surface proteins may be recovered from the solubilized cells and/or tissues.
  • the composition may further optionally comprise a protease inhibitor.
  • the compositions may be used to probe protein functional states and related skin cell signaling pathways.
  • Skin cell signaling pathways may be stress-induced, and may change over minutes to hours.
  • Phosphorylation is a highly labile post-translational modification that regulates many aspects of protein function. The ability to probe these functional states in the epidermis necessitates a fast and efficient method to solubilize and isolate phosphoproteins.
  • a method for recovering signaling proteins from skin cells comprising: contacting the skin cells with a composition comprising at least one of: (1) DPS and at least one of Brij 30, Brij 35, Brij 52, Brij C IO, and Brij 58; (2) DDPS and at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58; (3) TPS and at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58; (4) HPS and at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58; and (5) OPS and at least one of Brij 30, Brij 35, Brij 52, Brij CIO, and Brij 58, to provide solubilized signaling proteins; and subjecting the solubilized signaling proteins to reverse phase protein array.
  • compositions comprising at least one of: (1)
  • compositions are useful to disaggregate, solubilize, and stabilize components from living tissues in situ, from freshly resected tissues, frozen resected tissues, preserved paraffin embedded tissues, tissue and cell extracts and cultured cells derived from cell lines or resected tissues, and from exogenous agents such as viruses, bacteria, and prions.
  • compositions comprising at least one of: (1)
  • compositions may be useful to solubilize, remodel, and remove tissue hosting precancerous conditions such as actinic keratosis, leukoplakia, Barretts esophagus, and right-colon pre-cancer plaque, and surface cancers arising from any of these precancerous conditions.
  • tissue hosting precancerous conditions such as actinic keratosis, leukoplakia, Barretts esophagus, and right-colon pre-cancer plaque, and surface cancers arising from any of these precancerous conditions.
  • Other therapeutic uses may include solubilizing and removing tumors from a variety of surface or deep sites, or treating tumor surgical margins to remove any residual tumor cells at these sites.
  • the immune system may detect the dissolved tumor markers and initiate a potent anti-tumor immune response against these markers, leading to regression of the local tumor, as well as destruction of any systemic tumor cells carrying the detected tumor markers.
  • compositions comprising at least one of: (1)
  • compositions described herein may be useful to enhance absorption of topical therapeutics by removing diseased tissue, inflammatory cells, and thickened, hyper-keratinized skin that may block access to otherwise effective topical therapies.
  • An example of such a use is as a pre- treatment for psoriasis topical therapies, since psoriasis lesions typically have a hardened top layer or hyperkeratosis that inhibits absorption.
  • such treatment may include perturbation of the outer skin barrier using the compositions, and in some circumstances applied energy, to disrupt the barrier by disaggregation and solubilization of barrier cells and tissues, followed by application of the therapeutic molecules and drugs directly to the surface of the barrier-perturbed skin.
  • Example therapeutic molecules and drugs may include, for example, DNA-based drugs, R A-based drugs, protein-based drugs, peptide-based drugs, lipid-based drugs, carbohydrate-based drugs, small molecule drugs, nanoparticle based drugs, liposome-encapsulated drugs, and combinations of such classes of drugs.
  • compositions comprising at least one of: (1)
  • the introducing may include perturbation of the outer skin barrier using the compositions, and in some circumstances applied energy, to disrupt the barrier by disaggregation and solubilization of barrier cells and tissues, followed by application of the therapeutic or diagnostic molecules directly to the surface of the barrier-perturbed skin.
  • compositions comprising at least one of:
  • compositions may dissociate and dissolve diseased tissue directly after injection through a thin needle or catheter, the compositions may allow ablative surgery in areas that are not accessible to either open surgery or even to minimally invasive surgical instruments (such as in the vascular system, including arteries and coronary arteries).
  • minimally invasive surgical instruments such as in the vascular system, including arteries and coronary arteries.
  • DPS and at least one of Brij 30, Brij 35, Brij 52, Brij C I O, and Brij 58 may be useful to diminish or reduce intra-abdominal and peritoneal adhesions by dissolving specific bands of adherent tissue between intra-abdominal tissues and organs.
  • compositions comprising at least one of: (1)
  • the treatment may include contacting the compositions, and in some circumstances applied energy, to a wound's surrounding tissue to remove unhealthy tissue, including, for example, necrotic eschar and fibrinous slough.
  • compositions comprising at least one of: (1)
  • compositions comprising at least one of: (1)
  • the compositions may be useful to soften and/or dissolve hard and soft deposits on teeth and dentures.
  • compositions comprising at least one of: (1)
  • the compositions may be useful for treating aged, scarred, and UV-damaged skin, and removing and/or remodeling age spots, skin tags, seborrheic keratosis, scar tissues, xanthomas, non-cancerous hyperproliferative conditions, surface bumps, and scaly patches.
  • the use may include perturbation of the outer skin barrier using the compositions, and in some circumstances applied energy, to disrupt the barrier by disaggregation and solubilization of barrier cells and tissues.
  • the compositions may be introduced to deeper layers of skin to facilitate disaggregation, solubilization, and removal of structures associated with wrinkling, scarring, or both, of the skin surface.
  • compositions may be used to remove discoloration of the skin associated with previous injury, UV-damage, or aging.
  • the perturbation may be followed by application of therapeutic drugs or natural products and other cosmetic compositions that are believed or known to increase the smoothness, elasticity, and resilience of skin.
  • Such cosmetic compositions may include, for example, elastin or its peptides (e.g., V-V-P-Q), collagen or its peptides, resveratrol, idebenone, coenzyme Q10, acetyl hexapeptide-3, glycosaminoglycans, palmitoyl pentapeptide-4, sodium hyaluronate, and the like, and combinations thereof.
  • elastin or its peptides e.g., V-V-P-Q
  • collagen or its peptides e.g., resveratrol, idebenone
  • coenzyme Q10 e.g., acetyl hexapeptide-3, glycosaminoglycans, palmitoyl pentapeptide-4, sodium hyaluronate, and the like, and combinations thereof.
  • cell components recovered using the compositions may be introduced into biochemical assays to detect, quantify, and identify specific biomarkers associated with specific diseases.
  • the biochemical assays may include all molecular diagnostic assays for detecting DNA, RNA, proteins, peptides, lipids, carbohydrates, and small molecules, both endogenous and exogenous.
  • the biochemical assays to be used include PCR, ELISA, chromatography, gel analysis, electrophoresis, Western Blots, Southern Blots, Northern Blots, and other methods used in clinical laboratories for identification of molecular biomarkers of disease.
  • compositions comprising at least one of: (1)
  • Such use may involve impregnating an abrasive and absorbent swab (similar to a for-daily-use facial exfoliating sponge) with one or more of the compositions, and applying the swab to the region of interest with medium pressure in a twisting or back-and-forth motion onto target tissue for a predetermined time.
  • the depth may be controlled by the amount of pressure, as well as application time.
  • DPS, DDPS, TPS, HPS, and OPS were procured from Sigma-Aldrich as zwitterionic surfactants.
  • Brij 35, Brij 52, Brij CI O, and Brij 58 were procured from Sigma- Aldrich as nonionic surfactants.
  • a positive control was prepared by placing 1% v/v Triton X-100 (TX-1) in PBS.
  • Example 2 Protein recovery from porcine skin
  • Protein was recovered from porcine skin as a model tissue. Skin was procured in frozen form from Lampire Biological Laboratories Inc., and stored at -70 °C. Two hours before use, skin was thawed at room temperature (RT) and cut into small pieces (2.5 cm x 2.5 cm). Skin pieces were stripped off from subcutaneous fat and used without visible scratches or abrasions. Protein recovery was carried out by mounting the skin piece on a Franz diffusion cell (FDC) assembly (tissue exposure area of 1.77 cm 2 ; Permegear). The receiver chamber of the FDC was filled with PBS and the donor chamber was filled with 1 mL of surfactant combination as a sampling buffer. This buffer also acted as the coupling fluid between the ultrasound transducer and the tissue.
  • FDC Franz diffusion cell
  • Protein recovery was performed at RT with a 600-W probe sonicator (Sonics & Materials) operating at a frequency of 20 kHz.
  • the ultrasound transducer was placed at a distance of 5 mm from the tissue surface and an ultrasonic intensity of 2.4 W/cm 2 at 50% duty cycle was applied for 3 min.
  • the sampling buffer now containing solubilized tissue constituents, was aspirated and kept at -70 °C until analysis.
  • the solubilization ability for each surfactant formulation disclosed herein was quantified by the concentrations of total protein and solubilized protein (mg/ml). Supernatants were isolated from the samples using a centrifuge operating at 10,000 ⁇ g and 4 °C for 15 min. The solubilized protein amount was measured in the sample supernatant by using a colorimetric detection kit (Micro BCA Protein Assay Kit; Pierce).
  • Table 1 illustrates the total protein (mg/ml) recovered from porcine skin when the porcine skin is contacted with various combinations of zwitterionic and nonionic surfactants in the presence of ultrasound.
  • Figure 1 illustrates the same results in graphical form.
  • Table 2 illustrates the soluble protein (mg/ml) recovered from porcine skin when the porcine skin is contacted with those same combinations of zwitterionic and nonionic surfactants in the presence of ultrasound.
  • Figure 2 illustrates the results in graphical form.
  • TPS:Brij CIO was investigated for concentration effect.
  • the surfactant concentration was tested at total concentrations of 0.5%, 1 %, and 2% of TPS:Brij CI O, at a 1 : 1 ratio.
  • Figure 3 illustrates the dependence on concentration of TPS:Brij CI O on the soluble and total protein extraction efficacy from porcine skin.
  • GAPDH from rabbit was procured as a model enzyme from Sigma-
  • GAPDH powder was dissolved in ddH 0 (Milipore) to 90 U/ml and distributed into an E-tube, then stored at -80 °C until use. Enzyme protection was carried out by incubation of GAPDH in each combination disclosed herein, compared to that in PBS as a positive control. The concentration of GAPDH was fixed to 0.5 U/ml. GAPDH was incubated at 37 °C for 10 min. The activity of the GAPDH enzyme (U/ml) was assessed by KDalertTM GAPDH Assay Kit (Ambion, Inc, TX, USA).
  • Figure 4 illustrates in graphical form the preserved activity of GAPDH in each of the various combinations of zwitterionic and nonionic surfactants.
  • FIG. 5 illustrates in graphical form the combined dependence of soluble protein extraction efficacy and GAPDH stability in each of the various combinations of zwitterionic and nonionic surfactants.
  • HEK cells (HEKa-APF, Invitrogen, CA, USA) were cultured in a
  • Skin tissue was collected from euthanized mice and stored at -80 °C until use. About 10 mg of each tissue was placed in a 2 ml tube. 400 ⁇ of chilled lysis buffer (TX-1, TPS:Brij CI O, HPS:Brij 52, and OPS:Brij CI O) and protease inhibitor cocktail tablets (Roche Applied Science, IN, USA) were added to the tube (one tablet per 50 ml; one tablet contains Antipain-dihydrochloride 3mg, Aprotinin 0.5 mg, Bestatin 0.5 mg, Chymostatin lmg, E-64 3 mg, EDTA-Na 2 10 mg, Leupeptin 0.5 mg, Pefabloc SC 20 mg, Pepstatin 0.5 mg, and Phosphoramidon 3 mg).
  • Tissue was homogenized using a homogenizer (IKA, NC, USA) at 13,000 rpm for 1 min.
  • Figure 9 illustrates the total protein recovered from homogenized mouse skin using TPS:Brij C IO, HPS:Brij 52, and OPS:Brij CIO, as compared to TX-1.
  • Figure 10 illustrates the specific GAPDH activity measured in the homogenized mouse skin.

Abstract

L'invention concerne des compositions de solubilisation. Les compositions comprennent au moins un tensio-actif zwitterionique et au moins un tensio-actif non ionique. Dans un mode de réalisation, les compositions peuvent être utiles pour la solubilisation et le remodelage et/ou le retrait de tissu sur ou sous une peau d'un patient, facultativement conjointement avec l'application d'énergie à une région d'intérêt sur la peau. Dans un mode de réalisation, au moins un analyte peut être collecté et analysé à partir du tissu solubilisé.
EP12876815.7A 2012-05-16 2012-05-16 Compositions pour solubiliser des cellules et/ou un tissu Withdrawn EP2756061A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP16161790.7A EP3056559B1 (fr) 2012-05-16 2012-05-16 Compositions pour solubiliser des cellules et/ou un tissu

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/038169 WO2013172832A1 (fr) 2012-05-16 2012-05-16 Compositions pour solubiliser des cellules et/ou un tissu

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP16161790.7A Division EP3056559B1 (fr) 2012-05-16 2012-05-16 Compositions pour solubiliser des cellules et/ou un tissu

Publications (2)

Publication Number Publication Date
EP2756061A1 true EP2756061A1 (fr) 2014-07-23
EP2756061A4 EP2756061A4 (fr) 2014-08-13

Family

ID=49584087

Family Applications (2)

Application Number Title Priority Date Filing Date
EP12876815.7A Withdrawn EP2756061A4 (fr) 2012-05-16 2012-05-16 Compositions pour solubiliser des cellules et/ou un tissu
EP16161790.7A Active EP3056559B1 (fr) 2012-05-16 2012-05-16 Compositions pour solubiliser des cellules et/ou un tissu

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP16161790.7A Active EP3056559B1 (fr) 2012-05-16 2012-05-16 Compositions pour solubiliser des cellules et/ou un tissu

Country Status (10)

Country Link
EP (2) EP2756061A4 (fr)
JP (1) JP2015528691A (fr)
KR (1) KR102099487B1 (fr)
CN (1) CN104520418A (fr)
AU (2) AU2012380348B2 (fr)
BR (1) BR112014028239B1 (fr)
CA (1) CA2873707A1 (fr)
IN (1) IN2014MN02536A (fr)
MX (1) MX369625B (fr)
WO (1) WO2013172832A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026248A1 (fr) * 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions et procedes faisant appel a des combinaisons de detergents zwitterioniques
US20070183936A1 (en) * 2003-08-01 2007-08-09 Newsam John M Apparatus and methods for evaluating the barrier properties of a membrane
WO2010093861A2 (fr) * 2009-02-13 2010-08-19 The Regents Of The University Of Calfornia Système, procédé et dispositif de diagnostic à partir de tissu

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5358492A (en) * 1976-11-08 1978-05-26 Kao Corp Anti-foggig agent composition with lng lasting effect
US5639630A (en) * 1995-05-16 1997-06-17 Bayer Corporation Method and reagent composition for performing leukocyte differential counts on fresh and aged whole blood samples, based on intrinsic peroxidase activity of leukocytes
DK0934078T3 (da) * 1996-10-24 2003-04-14 Alza Corp Permeabilitetsfremmere til transdermal administrering af aktivstoffer, anordninger og fremgangsmåde til fremstilling deraf
KR100523685B1 (ko) * 1997-08-04 2005-10-26 가부시끼가이샤 센탈 세메 가가꾸 겐꾸쇼 Ｃ형 간염 바이러스의 코어 영역의 아미노산 서열을 인지하는 모노클로날 항체
US6589173B1 (en) 2000-07-17 2003-07-08 The Regents Of The University Of California Ultrasound system for disease detection and patient treatment
FR2848848B1 (fr) * 2002-12-19 2005-01-28 Oreal Composition de lavage des matieres keratiniques a base de tensioactif amphotere et de peg modifie par un groupe hydrophobe
US7186522B2 (en) * 2003-03-31 2007-03-06 Cytyc Corporation Papanicolau staining process
AU2004312067A1 (en) * 2003-12-30 2005-07-21 Wyeth Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
JP4422550B2 (ja) * 2004-05-25 2010-02-24 日華化学株式会社 親水性フッ素樹脂粒子の製造方法
WO2009048681A2 (fr) * 2007-08-06 2009-04-16 The Regents Of The University Of California Procédés de diagnostic à base de tissus
US8389582B2 (en) * 2007-08-06 2013-03-05 Samir Mitragotri Composition for solubilizing tissue comprising 3-(decyl dimethyl ammonio) propane sulfonate and tetraethylene glycol dodecyl ether
EP2278997B1 (fr) * 2008-04-21 2016-08-10 Nanobio Corporation Vaccin antigrippal à base de nanoémulsion
AU2009240389A1 (en) * 2008-04-25 2009-10-29 Nanobio Corporation Nanoemulsions for treating fungal, yeast and mold infections
US7700530B2 (en) * 2008-06-30 2010-04-20 Kimberly Clark Worldwide, Inc. Polysensorial personal care cleanser comprising a quaternary silicone surfactant
JP5382687B2 (ja) * 2008-11-12 2014-01-08 独立行政法人産業技術総合研究所 ルシフェリン−ルシフェラーゼ反応における発光強度の低下を抑制するための組成物及び方法
WO2010087964A2 (fr) * 2009-01-28 2010-08-05 Nanobio Corporation Composition pour le traitement et la prévention de l'acné, procédés de fabrication des compositions, et procédés d'utilisation associés
US20120064136A1 (en) * 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070183936A1 (en) * 2003-08-01 2007-08-09 Newsam John M Apparatus and methods for evaluating the barrier properties of a membrane
WO2006026248A1 (fr) * 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions et procedes faisant appel a des combinaisons de detergents zwitterioniques
WO2010093861A2 (fr) * 2009-02-13 2010-08-19 The Regents Of The University Of Calfornia Système, procédé et dispositif de diagnostic à partir de tissu

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HUANG ET AL: "Separation and measurement of desmosine and isodesmosine in vascular tissue hydrolysates by micellar electrokinetic capillary chromatography with a mixed micelle system", JOURNAL OF CHROMATOGRAPHY, ELSEVIER SCIENCE PUBLISHERS B.V, NL, vol. 1175, no. 2, 4 November 2007 (2007-11-04), pages 294-296, XP022373514, ISSN: 0021-9673, DOI: 10.1016/J.CHROMA.2007.10.091 *
S. PALIWAL ET AL: "One-step acquisition of functional biomolecules from tissues", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 33, 17 August 2010 (2010-08-17), pages 14627-14632, XP055124735, ISSN: 0027-8424, DOI: 10.1073/pnas.1004302107 *
See also references of WO2013172832A1 *

Also Published As

Publication number Publication date
AU2012380348B2 (en) 2017-02-23
CA2873707A1 (fr) 2013-11-21
MX2014013794A (es) 2015-04-08
EP2756061A4 (fr) 2014-08-13
EP3056559A2 (fr) 2016-08-17
IN2014MN02536A (fr) 2015-09-04
WO2013172832A1 (fr) 2013-11-21
BR112014028239A2 (pt) 2017-06-27
JP2015528691A (ja) 2015-10-01
CN104520418A (zh) 2015-04-15
MX369625B (es) 2019-11-14
BR112014028239B1 (pt) 2021-05-11
AU2012380348A1 (en) 2015-01-22
KR102099487B1 (ko) 2020-04-09
EP3056559A3 (fr) 2016-10-12
EP3056559B1 (fr) 2019-07-10
KR20150023394A (ko) 2015-03-05
AU2017203389A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
Baswan et al. Understanding the formidable nail barrier: A review of the nail microstructure, composition and diseases
Monedeiro et al. Investigation of sweat VOC profiles in assessment of cancer biomarkers using HS-GC-MS
JP2013521300A (ja) 抗菌ペプチド隔離化合物を用いた皮膚疾患および皮膚障害の処置のための組成物および方法
RU2605300C2 (ru) Способ оценки косметических средств
US20200315502A1 (en) Methods and Systems for Improved Collection of Interstitial Fluid
Rolland et al. Hairy skin exposure to VX in vitro: effectiveness of delayed decontamination
Brown et al. The art and science of dermal formulation development
WO2018043636A1 (fr) Procédé de préparation d'un échantillon pour l'analyse ou l'observation de la peau
US20170105673A1 (en) Methods for Solubilizing Cells and/or Tissue
US8389582B2 (en) Composition for solubilizing tissue comprising 3-(decyl dimethyl ammonio) propane sulfonate and tetraethylene glycol dodecyl ether
Al-Marabeh et al. A prodrug approach to enhance azelaic acid percutaneous availability
AU2012380348B2 (en) Compositions for solubilizing cells and/or tissue
JP6527195B2 (ja) 細胞および／または組織を可溶化するための組成物
Erchiga et al. Pityriasis versicolor and other Malassezia skin diseases
AU2016346203A1 (en) Isotretinoin formulations and uses and methods thereof
WO2022009873A1 (fr) Stabilisateur d'arn
Svoboda Adaptation of conventional and modern non-invasive methods for analysis of photoaged human skin barrier
US9814422B2 (en) Compositions for solubilizing cells and/or tissue
Dong Influences of skin barrier, a nanoparticle-based vehicle and solvents on cutaneous drug delivery
EP3922714A1 (fr) Utilisation d'un modèle de peau en 3d pour évaluer le traitement d'une infection sars-coronavirus de la peau
Kahsay Formulation and characterization of colloidal formulations loaded with free amino acids for dermal delivery
WO2015162552A2 (fr) Composition à usage topique
Escobar-Chávez et al. Conventional methods for cutaneous drug sampling
Hafeez et al. Microbiology of the Skin
Robinson The Natural Moisturizing Factor of the Skin: Effects of Barrier Perturbation and Anatomical Location and Relation to Biophysical Measurements

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140404

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20140710

RIC1 Information provided on ipc code assigned before grant

Ipc: C11D 1/88 20060101AFI20140704BHEP

Ipc: C07K 1/14 20060101ALI20140704BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HWANG, BYEONG, HEE

Inventor name: LEBOVITZ, RUSSELL, M.

Inventor name: MITRAGOTRI, SAMIR

17Q First examination report despatched

Effective date: 20150616

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161014